Design, synthesis, bioactivity, X-ray crystallography, and molecular docking studies of chrysin-1,3,5-triazine derivatives as anticancer agents
Bioorganic Chemistry · 2025-07 · 161 · 108486
DOI: 10.1016/j.bioorg.2025.108486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025-07. Verfasst von Xuan-Yi Xue und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jiangsu Key Laboratory of Marine Bioresources and Environment, Co-Innovation Center of Jiangsu Marine Bio-industry Technology, Ji…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Flavonoids, Triazines, Molecular Docking Simulation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: JIangsu Education Department, Graduate Research and Innovation Projects of Jiangsu Province.
Abstract (Originalsprache)
In order to discover new effective anti-cancer drugs, fifteen derivatives of chrysin-1,3,5-triazine were designed and synthesized as potential novel anti-cancer agents. The structure of the target compounds were characterized by 1H NMR, 13C NMR, IR, and HR-MS. The purity of all compounds were detected by HPLC. The structure of compound 4a was subjected to further investigation through single crystal X-ray diffraction, and elaborate discussions were conducted on the Hirshfeld surface and two-dimensional fingerprint diagram to explore the molecular conformation, crystal packing mode and molecular interactions. The antiproliferative activity of these compounds was assessed by the MTT (methylthiazolyl tetrazolium) assay against MDA-MB-231 (breast cancer cells), HeLa (cervical cancer cells), HCCLM3 (liver cancer cells), and HCT116 (colon cancer cells). Positive controls were cisplatin and chrysin. The results show that some chrysin-1,3,5-triazine derivatives have better anti-cancer activity than cisplatin and chrysin. Chrysin-1,3,5-triazine derivatives selectively targets HeLa cervical cancer cells. Compound 4c (7-((4-(Dibutylamino)-1,3,5-triazin-2-yl)oxy)-5-hydroxy-2-phenyl-4H-chromen-4-one) exhibits the strongest antiproliferative activity against HeLa cells (IC50 = 9.86 ± 0.37 μM), superior to cisplatin and chrysin (IC50 values of 28.09 ± 0.47 μM and 29.51 ± 0.51 μM, respectively). Further studies showed that compound 4c not only inhibits the invasion, adhesion, and proliferation of HeLa cells, but also has a strong inhibitory effect on the proliferation of HeLa tumor heterotopic xenografts in vivo. Molecular docking studies suggest that compound 4c can interact with phosphatidylinositol 3-kinase(PI3K)and cysteine aspartic acid proteinase-3 (Caspase-3). Western blot results demonstrated that compound 4c inhibited PI3K expression at the protein level and promoted the degradation of Pro-caspase-3, thereby activating the caspase-3-dependent apoptotic pathway. Furthermore, the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of these compounds suggest that they may have pharmacological characteristics and safety. Thus, compound 4c has the potential to be a highly promising candidate for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Jiangsu Key Laboratory of Marine Bioresources and Environment, Co-Innovation Center of Jiangsu Marine Bio-industry Technology, Jiangsu Ocean University, Lianyungang 222005, People's Republic of China.
- Jiangsu Henghai Pharmaceutical Research Institute Co., LTD, Lianyungang 222005, People's Republic of China.
- School of Pharmacy, Jiangsu Key Laboratory of Marine Bioresources and Environment, Co-Innovation Center of Jiangsu Marine Bio-industry Technology, Jiangsu Ocean University, Lianyungang 222005, People's Republic of China…
Förderung
- JIangsu Education Department
- Graduate Research and Innovation Projects of Jiangsu Province
Zitieren
APA
Xue, X. Y., He, J. L., Song, M. W., Yu, Z. E., Shuang-Liu, Lin, M. J., Zhang, C. P., Bo-Ding, Hao-Wang, Ma, Z. H., Zhang, W. H., Zou, Y. Y., Qing-Yuan, Jing-Ji, & Shi, D. H. (2025). Design, synthesis, bioactivity, X-ray crystallography, and molecular docking studies of chrysin-1,3,5-triazine derivatives as anticancer agents. Bioorganic Chemistry, 161, 108486. https://doi.org/10.1016/j.bioorg.2025.108486
Vancouver
Xue XY, He JL, Song MW, Yu ZE, Shuang-Liu, Lin MJ, et al. Design, synthesis, bioactivity, X-ray crystallography, and molecular docking studies of chrysin-1,3,5-triazine derivatives as anticancer agents. Bioorganic Chemistry. 2025;161:108486. doi:10.1016/j.bioorg.2025.108486
BibTeX
@article{Xue2025,
author = {Xue, Xuan-Yi and He, Jing-Liang and Song, Meng-Wei and Yu, Zi-En and Shuang-Liu and Lin, Meng-Jie and Zhang, Chi-Peng and Bo-Ding and Hao-Wang and Ma, Zhi-Hao and Zhang, Wei-Heng and Zou, Yang-Yang and Qing-Yuan and Jing-Ji and Shi, Da-Hua},
title = {Design, synthesis, bioactivity, X-ray crystallography, and molecular docking studies of chrysin-1,3,5-triazine derivatives as anticancer agents},
journal = {Bioorganic Chemistry},
year = {2025},
volume = {161},
pages = {108486},
doi = {10.1016/j.bioorg.2025.108486}
}
EUVIMED